DOCSLIB.ORG

Geïntegreerd Tarief Van De Europese Gemeenschappen (TARIC) Volumen IV — Bijlagen (96/C 98 A/01 )

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Geïntegreerd Tarief Van De Europese Gemeenschappen (TARIC) Volumen IV — Bijlagen (96/C 98 A/01 ) 1 . 4 . 96 NL Publikatieblad van de Europese Gemeenschappen 3101 I (Mededelingen) COMMISSIE Geïntegreerd tarief van de Europese Gemeenschappen (TARIC) Volumen IV — Bijlagen (96/C 98 A/01 ) INHOUD Bladzijde Bijlage 1 : Aanvullende codes voor de agrarische elementen , aanvullende codes en aanvul­ lende rechten voor suiker en meel en referentieprijzen voor visserijprodukten . 3103 Bijlage 2 : Lijst voor farmaceutische stoffen 3169 Bijlage 3 : CITES 3277 1 . 4 . 96 l NL ! Publikatieblad van de Europese Gemeenschappen 3103 BIJLAGE 1 — AANVULLENDE CODES VOOR DE AGRARISCHE ELEMENTEN — AANVULLENDE CODES EN AANVULLENDE RECHTEN VOOR SUIKER EN MEEL — REFERENTIEPRIJZEN VOOR VISSERIJPRODUCTEN 3104 NL Publikatieblad van de Europese Gemeenschappen 1 . 4 . 96 AANVULLENDE CODES VOOR TABEL VAN DE HOOFD Aanvullende code voor bepaalde goederen > 0<5 Melkvet Melkproteïnen GN-code (gewichtspercenten) (gewichtspercenten) C ) >0 >5 > 30 > 50 <5 < 30 < 50 < 70 0405 20 10 1905 30 11 > 0<1,5 > 0 < 2,5 7000 7001 7002 7003 7004 0405 20 30 1905 30 19 > 2,5 < 6 7020 7021 7022 7023 7024 1905 30 30 > 6 < 18 7040 7041 7042 7043 7044 1704 90 51 1905 30 51 > 18 < 30 7060 7061 7062 7063 7064 1704 90 55 1905 30 59 > 30 < 60 7080 7081 7082 7083 7084 1704 90 61 1905 30 91 > 60 7800 7801 7802 x x 1704 90 65 1905 30 99 1704 90 71 1905 40 10 > 1 ,5 < 3 > 0 < 2,5 7100 7101 7102 7103 7104 1704 90 75 1 905 40 90 > 2,5 <6 7120 7121 7122 7123 7124 1704 90 81 1905 90 30 > 6 < 1 8 7140 7141 7142 7143 7144 1704 90 99 1905 90 40 > 1 8 < 30 7160 7161 7162 7163 7164 1905 90 45 > 30 < 60 7180 7181 7182 7183 x 1806 20 10 1905 90 55 > 60 7820 7821 7822 x x 1806 20 30 1905 90 60 1806 20 50 1905 90 90 > 3<6 > 0 < 2,5 7840 7841 7842 7843 7844 1806 20 70 > 2,5 < 1 2 7200 7201 7202 7203 7204 1806 20 80 2004 10 91 > 12 7260 7261 7262 7263 7264 1806 20 95 2005 20 10 1806 31 00 1806 32 10 2101 1298 > 6<9 > 0<4 7860 7861 7862 7863 7864 1806 32 90 2101 20 98 > 4 < 15 7300 7301 7302 7303 7304 1806 90 11 2106 10 80 > 15 7360 7361 7362 7363 7364 1806 90 19 2106 90 98 1806 90 31 > 9<12 > 0<6 7900 7901 7902 7903 7904 1806 90 39 > 6 < 1 8 7400 7401 7402 7403 7404 1806 90 50 > 18 7460 7461 7462 7463 7464 1806 90 60 1806 90 70 > 12<18 > 0<6 7940 7941 7942 7943 7944 1806 90 90 > 6 < 1 8 7500 7501 7502 7503 7504 > 18 7560 7561 7562 7563 7564 1901 10 00 1901 20 00 > 1 8 < 26 > 0<6 7960 7961 7962 7963 7964 1901 90 99 >6 7600 7601 7602 7603 7604 1904 20 10 > 26 < 40 > 0<6 7980 7981 7982 7983 7984 >6 7700 7701 7702 7703 x > 40 < 55 7720 7721 7722 7723 x > 55 < 70 7740 7741 7742 x x > 70 < 85 7760 7761 7762 x x > 85 7780 7781 x x x (') Caseïne en caseïnaten gebruikt in de samenstelling van een produkt worden niet beschouwd als melkproteïnen in het geval dat het produkt geen andere melkbestanddelen bevat. Melkvet in het produkt aanwezig voor minder dan 1 gewichtspercent, en lactose voor minder dan 1 gewichtspercent, worden niet aangemerkt als andere melkbestanddelen . Bij het vervullen van de douaneformaliteiten is belanghebbende verplicht in de aangifte te vermelden : «enig melkbestanddeel : caseïne/caseïnaat", indien dit het geval is . ( 2) Het gehalte van de goederen (in oorspronkelijke toestand) aan zetmeel, afbraakprodukten daarvan — met inbegrip van alle glucosepolymeren — en de eventueel aanwezige glucose, bepaald op basis van glucose en uitgedrukt in zetmeel (watervrij, 100 % zuiver; omrekeningsfactor van glucose naar zetmeel : 0,9). Als een mengsel van glucose en fructose wordt aangegeven (in welke vorm dan ook) of in de goederen wordt aangetroffen , wordt echter slechts dat deel van de glucose in bovenstaande berekening opgenomen, dat overeenkomt met het verschil tussen de hoeveelheid glucose en fructose . (3) Het gehalte van de goederen (in oorspronkelijke toestand) aan saccharose, vermeerderd met de hoeveelheid saccharose die het resultaat is van de omre­ kening van alle mengsels van glucose en fructose naar saccharose (rekenkundige som van de hoeveelheden van deze twee suikers, vermenigvuldigd met 0,95), die wordt aangegeven (in welke vorm dan ook) of in de goederen wordt aangetroffen . Als de hoeveelheid fructose lager is dan de hoeveelheid glucose , wordt echter slechts dat deel van de glucose in bovenstaande berekening opgenomen, waarvan het gewicht gelijk is aan de hoeveelheid fructose . NB: Wanneer de aanwezigheid van een hydrolysaat van lactose wordt aangegeven en/of een hoeveelheid galactose bij de suikers wordt aangetoond, wordt in alle gevallen de aan de hoeveelheid galactose equivalente hoeveelheid glucose afgetrokken van de totale hoeveelheid glucose, voordat enige andere berekening wordt uitgevoerd . 1 . 4 . 96 | NL Publikatieblad van de Europese Gemeenschappen 3105 DE AGRARISCHE ELEMENTEN STUKKEN 14-17-18-19-20-21 opgenomen in Verordening (EG) nr. 3448/93 Zetmeel / glucose (gewichtspercenten) (2) >5 < 25 > 25 < 50 > 50 < 75 > 75 Saccharose / invertsuiker / isoglucose (gewichtspercenten) (3) >0 >5 > 30 > 50 >0 >5 > 30 >0 >5 >0 > 70 > 50 > 30 >5 <5 < 30 < 50 < 70 <5 < 30 < 50 <5 < 30 <5 7005 7006 7007 7008 7009 7010 7011 7012 7013 7015 7016 7017 7758 7759 7025 7026 7027 7028 7029 7030 7031 7032 7033 7035 7036 7037 7768 7769 7045 7046 7047 7048 7049 7050 7051 7052 7053 7055 7056 7057 7778 7779 7065 7066 7067 7068 7069 7070 7071 7072 7073 7075 7076 7077 7788 7789 7085 7086 7087 7088 x 7090 7091 7092 x 7095 7096 x x x 7805 7806 7807 x x 7810 7811 x x x x x x x 7105 7106 7107 7108 7109 7110 7111 7112 7113 7115 7116 711 7 7798 7799 7125 7126 7127 7128 7129 7130 7131 7132 7133 7135 7136 7137 7808 7809 7145 7146 7147 7148 7149 7150 7151 7152 7153 7155 7156 7157 7818 7819 7165 7166 7167 7168 7169 7170 7171 7172 7173 7175 7176 7177 7828 7829 7185 7186 7187 7188 x 7190 7191 7192 x 7195 7196 x x x 7825 7826 7827 x x 7830 7831 x x x x x x x 7845 7846 7847 7848 7849 7850 7851 7852 7853 7855 7856 7857 7858 7859 7205 7206 7207 7208 7209 7210 7211 7212 7213 7215 7216 7217 7220 7221 7265 7266 7267 7268 7269 7270 7271 7272 7273 7275 7276 x 7838 x 7865 7866 7867 7868 78 69 7870 7871 7872 7873 7875 7876 7877 7878 7879 7305 7306 7307 7308 7309 7310 7311 7312 7313 7315 7316 7317 7320 7321 7365 7366 7367 7368 7369 7370 7371 7372 7373 7375 7376 x 7378 x 7905 7906 7907 7908 7909 7910 7911 7912 7913 7915 7916 7917 7918 7919 7405 7406 7407 7408 7409 7410 7411 7412 7413 7415 7416 7417 7420 7421 7465 7466 7467 7468 x 7470 7471 7472 x 7475 7476 x x x 7945 7946 7947 7948 7949 7950 7951 7952 7953 7955 7956 7957 7958 7959 7505 7506 7507 7508 7509 7510 7511 7512 7513 7515 7516 7517 7520 7521 7565 7566 7567 7568 x 7570 7571 7572 x 7575 7576 x x x 7965 7966 7967 7968 7969 7970 7971 7972 7973 7975 7976 7977 7978 7979 7605 7606 7607 7608 7609 7610 7611 7612 7613 7615 7616 x 7620 x 7985 7986 7987 7988 x 7990 7991 7992 x 7995 7996 x x x 7705 7706 7707 7708 x 7710 7711 7712 x 7715 7716 x x x 7725 7726 7727 7728 x 7730 7731 7732 x 7735 7736 x x x 7745 7746 7747 x x 7750 775 1 x x x x x x x 7765 7766 x x x 7770 7771 x x x x x x x 7785 7786 x x x x x x x x x x x x 3106 rNLi Publikatieblad van de Europese Gemeenschappen 1 . 4 . 96 AANVULLENDE CODES EN AANVULLENDE RECHTEN VOOR SUIKER EN MEEL ERGA OMNES-CEE EA AD S/Z AD F/M EA AD S/Z AD F/M Aanvullende Aanvullende code code Ecum/ 100 kg/net Ecum/100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net 7000 0 0 0 7060 107.67 0 0 7001 12.16 12.16 0 7061 119.82 12.16 0 7002 22.8 22.8 0 7062 130.46 22.8 0 7003 32.93 32.93 0 7063 130.63 32.93 0 7004 47.12 47.12 0 7064 151.8 47.12 0 7005 6.11 0 6.11 7065 113.77 0 6.11 7006 18.27 12.16 6.11 7066 125.93 12.16 6.11 7007 28.9 22.8 6.11 7067 136.56 22.8 6.11 7008 39.03 32.93 6.11 7068 143.72 32.93 6.11 7009 53.22 47.12 6.11 7069 157.91 47.12 6.11 7010 13.05 0 13.05 7070 120.71 0 13.05 7011 25.21 12.16 13.05 7071 132.88 12.16 13.05 7012 35.84 22.8 13.05 7072 143.5 22.8 13.05 7013 45.98 32.93 13.05 7073 150.68 32.93 13.05 7015 20.54 0 20.54 7075 125.24 0 20.54 7016 32.7 12.16 20.54 7076 137.4 12.16 20.54 7017 43.34 22.8 20.54 7077 148.02 22.8 20.54 7020 20.1 0 0 7080 209.58 0 0 7021 32.26 12.16 0 7081 221.74 12.16 0 7022 42.89 22.8 0 7082 232.39 22.8 0 7023 52.48 32.93 0 7083 236.73 32.93 0 7024 66.66 47.12 0 7084 250.91 47.12 0 7025 26.21 0 6.11 7085 215.69 0 6.11 7026 38.37 12.16 6.11 7086 227.84 12.16 6.11 7027 49 22.8 6.11 7087 238.48 22.8 6.11 7028 58.58 32.93 6.11 7088 242.84 32.93 6.11 7029 72.77 47.12 6.11 7090 222.62 0 13.05 7030 33.14 0 13.05 7091 234.81 12.16 13.05 7031 45.3 12.16 13.05 7092 245.43 22.8 13.05 7032 55.94 22.8 13.05 7095 224.34 0 20.54 7033 65.52 32.93 13.05 7096 236.51 12.16 20.54 7035 40.08 0 20.54 7100 8.36 0 0 7036 52.24 12.16 20.54 7101 20.51 12.16 0 7037 62.89 22.8 20.54 7102 31.15 22.8 0 7040 60.29 0 0 7103 41.28 32.93 0 7041 72.45 12.16 0 7104 55.47 47.12 0 7042 83.08 22.8 0 7105 14.46 0 6.11 7043 91.56 32.93 0 7106 26.62 12.16 6.11 7044 105.74 47.12 0 7107 37.26 22.8 6.11 7045 66.4 0 6.11 7108 47.39 32.93 6.11 7046 78.56 12.16 6.11 7109 61.57 47.12 6.11 7047 89.19 22.8 6.11 7110 21.4 0 13.05 7048 97.66 32.93 6.11 7111 33.55 12.16 13.05 7049 111.85 47.12 6.11 7112 44.2 22.8 13.05 7050 73.34 0 13.05 7113 54.33 32.93 13.05 7051 85.5 12.16 13.05 7115 28.9 0 20.54 7052 96.13 22.8 13.05 7116 41.06 12.16 20.54 7053 104.6 32.93 13.05 7117 51.69 22.8 20.54 7055 79.17 0 20.54 7120 28.45 0 0 7056 91.34 12.16 20.54 7121 40.61 12.16 0 7057 101.97 22.8 20.54 7122 51.25 22.8 0 1 .
Load more

Recommended publications
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • 5-HT2A/2C Receptor Modulation of Absence Seizures and Characterization of the GHB-Model
    5-HT2A/2C receptor modulation of absence seizures and characterization of the GHB-model A thesis submitted to Cardiff University for the degree of Doctor of Philosophy by Marcello Venzi (MSc) School of Biosciences, Cardiff University, October 2014 Chapter 1 Declaration and Statements This work has not been submitted in substance for any other degree or award at this or any other university or place of learning, nor is being submitted concurrently in candidature for any degree or other award. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 1 This thesis is being submitted in partial fulfillment of the requirements for the degree of PhD . Signed ………………………………………… (candidate) Date ………………………… STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated. Other sources are acknowledged by explicit references. The views expressed are my own. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loan, and for the title and summary to be made available to outside organisations. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loans after expiry of a bar on access previously approved by the Academic Standards & Quality Committee. Signed ………………………………………… (candidate) Date ………………………… II Chapter 1 Summary Absence seizures (ASs) are non-convulsive epileptic events which are common in pediatric and juvenile epilepsies. They consist of EEG generalized spike-and-wave-discharges (SWDs) accompanied by an impairment of consciousness and are expressed within the thalamocortical network.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • 30 November 1994 MARRAKESH AGREEMENT ESTABLISHING THE
    ACCORD GENERAL ACUERDO GENERAL SUR LES TARIFS DOUANIERS 5 ^ SOBRE ARANCELES ADUANEROS ET LE COMMERCE VJtBÀEU Y COMERCIO GENERAL AGREEMENT ON TARIFFS AND TRADE Centre William Rappard Téléphone: (41 22) 739 51 11 Rue de Lausanne 154 Ligne directe: (41 22) 739 5076 Case postale Telefax: (41 22) 731 42 06 CH - 1211 Genève 21 Télex: 412 324 GATT CH Télégramme: GATT, GENÈVE Référence: GLI/303 30 November 1994 MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION DONE AT MARRAKESH ON 15 APRIL 19199S 4 PROCES-VERBAL OF RECTIFIC In documents G/RS/6 and G/RS/7 proposed rectification*ttiorSto Schedule XXXVIII - Japan annexed to the Marrakesh Protocol to the General Ajffeehoent on Tariffs and Trade 1994 were circulated to the Participants in the Uruguay Roand ofjvlultilateral Trade Negotiations. Considering that no objections to these rectifications ravebeen raised during the thirty-day period established for such action, these rectifications have been approved. The relevant texts are annexed hereto. I J Acting as depositary of the Marrakesh Agreement Establishing the World Trade Organization, I have caused these rectifications to be made in the authentic text and have initialled these rectification:tiîLcatior s in the relevant schedule annexed to the Marrakesh Protocol. In witness whereof I have signed the present Procès-Verbal of Rectification, drawn up in the English, French anid SpanisSper h languages, on 30 November 1994. O Peter D. Sutherland O Director-General 94-2611 Let/1953 Accord générât sur les Tarif* douanier* et le Commerce General Agreement on Tariffs and Trade Page 2 MARRAKESH PROTOCOL TO THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994 Schedule XXXVIII - Japan The following corrections should be made in "Schedule XXXVIII - Japan": 1.
    [Show full text]
  • Trabajo De Diploma
    Facultad de Química-Farmacia Departamento de Farmacia Trabajo de diploma Título: Evaluación experimental “in vivo” de nuevos compuestos con actividad analgésica seleccionados a través del tamizaje virtual. Autor: Yulier León Mederos Tutores: Dr. Yovani Marrero Ponce MSc. Arelis López Sacerio 2009-2010 Exergo Todos y cada uno de nosotros paga puntualmente su cuota de sacrificio consciente de recibir el premio en la satisfacción del deber cumplido, conscientes de avanzar con todos hacia el Hombre Nuevo que se vislumbra en el horizonte... Che Yulier León Mederos Evaluación experimental “in vivo” de nuevos compuestos con actividad analgésica seleccionados a través del tamizaje virtual Dedicatoria A alguien que se lo merece, por su ayuda y su apoyo durante esta larga carrera como estudiante universitario, mi madre la cual confió siempre en mí y por ver esperado con paciencia esta gran hazaña. Elisa Jorge por verse convertido en mi madre y por su apoyo incondicional cada día que transcurrió en esta escuela. A mis hermanos por estar siempre a mí lado cuando más yo los necesitaba, a mi abuela que no pudo disfrutar esta gran victoria junto a mí, pero allá donde ella está le llegará este lindo regalo. Yulier León Mederos Evaluación experimental “in vivo” de nuevos compuestos con actividad analgésica seleccionados a través del tamizaje virtual Agradecimientos Esta página está dedicada a todas aquellas personas que de un modo u otro hicieron posible la realización de esta tesis. Quisiera agradecer en primer lugar a mi madre que siempre depositó todo su amor y confianza en mí, sobre todo en los momentos difíciles a lo largo de mi carrera A mis hermanos ya que sus consejos siempre fueron buenos y por el aprecio que siento hacia ellos.
    [Show full text]
  • Effect of Acute Administration of the 5-HT1A Receptor Ligand, Lesopitron, on Rat Cortical 5-HT and Dopamine Turnover 'M
    Br. J. Pharmacol. (1994), 113, 425-430 IF" Macmillan Press Ltd, 1994 Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover 'M. Ballarin, A. Carceller & X. Guitart Neurochemistry Unit, C.N.S. Department, Laboratories Dr. Esteve, Avda. Mare de Deu de Montserrat 221, 08026 Barcelona, Spain 1 The involvement of presynaptic 5-hydroxytryptaminelA (5-HTIA) autoreceptors in the anxiolytic-like properties of lesopitron (E-4424) (2-{4-[4-(4-chloro-l-pyrazolyl)butyl]-l-piperazinyl)pyrimidine) was studied. Brain microdialysis was used to examine the effect of the drug on the release of 5- hydroxytryptamine (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the frontal cortex of awake, freely moving rats. Moreover, extracellular cortical 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were also studied to assess the possible participation of dopaminergic systems. 2 Lesopitron administered at a dose which induces anxiolytic behaviour in rats (30 ;Lg kg-', i.p.) markedly reduced 5-HT levels (to 45% of the basal value) in cortical perfusates, having no effect on 5-HIAA, DOPAC and HVA. The effects of lesopitron were compared with those produced by the anxiolytic, and structurally related compound, buspirone. 3 Buspirone administered at a dose inducing anxiolytic-like effects in rats (5 mg kg-', i.p.) produced a marked decrease in cortical 5-HT levels (to 20% of the basal value), but in contrast to lesopitron, buspirone produced a pronounced increase in cortical DOPAC (to 300% of the basal value) and HVA (to 400% of the basal value) levels.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]